Requirements for effective antitumor responses of TCR transduced T cells

Journal of Immunology

Volumn 181, Issue 7, 2008, Pages 5128-5136

  De Witte, Moniek A ^a   Jorritsma, Annelies ^a   Kaiser, Andrew ^a   Van Den Boom, Marly D ^a   Dokter, Maarten ^a   Bendle, Gavin M ^a   Haanen, John B A G ^a   Schumacher, Ton N M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; T LYMPHOCYTE RECEPTOR; VACCINE; CANCER VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR; OVALBUMIN; VIRUS VACCINE;

ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER GRAFT; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; CELL TRANSFER; CONTROLLED STUDY; DNA MODIFICATION; GENETIC TRANSDUCTION; HOST; IMMUNE RESPONSE; IN VIVO STUDY; IRRADIATION; MELANOMA; MOUSE; NONHUMAN; PRECURSOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; CD8+ T LYMPHOCYTE; EXPERIMENTAL MELANOMA; GAMMA RADIATION; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; PATHOLOGY; RADIATION EXPOSURE; RETROVIRUS; TRANSGENIC MOUSE; TRANSPLANTATION; TUMOR CELL LINE; WHOLE BODY RADIATION;

ADOPTIVE TRANSFER; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; GAMMA RAYS; GENETIC VECTORS; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; OVALBUMIN; RECEPTORS, ANTIGEN, T-CELL; RETROVIRIDAE; TRANSDUCTION, GENETIC; TRANSPLANTATION CONDITIONING; VIRAL VACCINES; WHOLE-BODY IRRADIATION;

EID: 58149296551     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.7.5128     Document Type: Article

References (43)

1. Coccoris, M., M. A. de Witte, and T. N. M. Schumacher. 2005. Prospects and limitations of T cell receptor gene therapy. Curr. Gene Ther. 5: 583-593. (Pubitemid 43009503)
2. Calogero, A., G. A. Hospers, K. M. Kruse, P. I. Schrier, N. H. Mulder, E. Hooijberg, and L. F. de Leij. 2000. Retargeting of a T cell line by anti MAGE- 3/HLA-A2 α βTCR gene transfer. Anticancer Res. 20: 1793-1799. (Pubitemid 30628203)
3. Clay, T. M., M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura. 1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 163: 507-513.
4. Engels, B., E. Noessner, B. Frankenberger, T. Blankenstein, D. J. Schendel, and W. Uckert. 2005. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum. Gene Ther. 16: 799-810. (Pubitemid 40982329)
5. Morgan, R. A., M. E. Dudley, Y. Y. Yu, Z. Zheng, P. F. Robbins, M. R. Theoret, J. R. Wunderlich, M. S. Hughes, N. P. Restifo, and S. A. Rosenberg. 2003. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J. Immunol. 171: 3287-3295.
6. Tsuji, T., M. Yasukawa, J. Matsuzaki, T. Ohkuri, K. Chamoto, D. Wakita, T. Azuma, H. Niiya, H. Miyoshi, K. Kuzushima, et al. 2005. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes. Blood 106: 470-476. (Pubitemid 40981240)
7. Zhao, Y., Z. Zheng, P. F. Robbins, H. T. Khong, S. A. Rosenberg, and R. A. Morgan. 2005. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 174: 4415-4423. (Pubitemid 40396025)
8. Jorritsma, A., R. Gomez-Eerland, M. Dokter, W. van de Kasteele, Y. M. Zoet, I. I. Doxiadis, N. Rufer, P. Romero, R. A. Morgan, T. N. Schumacher, and J. B. Haanen. 2007. Selecting highly affine and well expressed TCRs for gene therapy of melanoma. Blood 110: 3564-3572. (Pubitemid 350159623)
9. Scholten, K. B., D. Kramer, E. W. Kueter, M. Graf, T. Schoedl, C. J. Meijer, M. W. Schreurs, and E. Hooijberg. 2006. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin. Immunol. 119: 135-145.
10. Cohen, C. J., Y. Zhao, Z. Zheng, S. A. Rosenberg, and R. A. Morgan. 2006. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66: 8878-8886.
11. Cohen, C. J., Y. F. Li, M. El Gamil, P. F. Robbins, S. A. Rosenberg, and R. A. Morgan. 2007. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67: 3898-3903.
12. Kuball, J., M. L. Dossett, M. Wolfl, W. Y. Ho, R. H. Voss, C. Fowler, and P. D. Greenberg. 2007. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109: 2331-2338. (Pubitemid 46425872)
13. Schumacher, T. N. 2002. T-cell-receptor gene therapy. Nat. Rev. Immunol. 2: 512-519.
14. Kessels, H. W., M. C. Wolkers, M. D. van den Boom, M. A. van der Valk, and T. N. Schumacher. 2001. Immunotherapy through TCR gene transfer. Nat. Immunol. 2: 957-961.
15. Kessels, H. W., K. Schepers, M. D. van den Boom, D. J. Topham, and T. N. Schumacher. 2006. Generation of T cell help through a MHC class I-restricted TCR. J. Immunol. 177: 976-982.
16. Morris, E. C., A. Tsallios, G. M. Bendle, S. A. Xue, and H. J. Stauss. 2005. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc. Natl. Acad. Sci. USA 102: 7934-7939.
17. de Witte, M. A., M. Coccoris, M. C. Wolkers, M. D. van den Boom, E. M. Mesman, J. Y. Song, M. van der Valk, J. B. Haanen, and T. N. Schumacher. 2006. Targeting self-antigens through allogeneic TCR gene transfer. Blood 108: 870-877.
18. De Witte, M. A., G. M. Bendle, M. D. van den Boom, M. Coccoris, T. D. Schell, S. S. Tevethia, H. Van Tinteren, E. M. Mesman, J. Y. Song, and T. N. Schumacher. 2008. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J. Immunol. 181: 2563-2571.
19. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129.
20. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
21. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
22. Kurts, C., J. F. Miller, R. M. Subramaniam, F. R. Carbone, and W. R. Heath. 1998. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med. 188: 409-414. (Pubitemid 28357770)
23. + T cells in vivo. J. Immunol. 166: 4355-4362.
24. Goldrath, A. W., L. Y. Bogatzki, and M. J. Bevan. 2000. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J. Exp. Med. 192: 557-564.
25. + T cells. Curr. Opin. Immunol. 10: 444-449.
26. Kaech, S. M., and R. Ahmed. 2003. Immunology: CD8 T cells remember with a little help. Science 300: 263-265.
27. Dummer, W., A. G. Niethammer, R. Baccala, B. R. Lawson, N. Wagner, R. A. Reisfeld, and A. N. Theofilopoulos. 2002. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110: 185-192. (Pubitemid 34787355)
28. + T cells in lymphopenic hosts. Immunity 11: 183-190.
29. Inoue, K., H. Tamaki, H. Ogawa, Y. Oka, T. Soma, T. Tatekawa, Y. Oji, A. Tsuboi, E. H. Kim, M. Kawakami, et al. 1998. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 91: 2969-2976. (Pubitemid 28227548)
30. Epping, M. T., L. Wang, M. J. Edel, L. Carlee, M. Hernandez, and R. Bernards. 2005. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122: 835-847.
31. Adams, G. P., and L. M. Weiner. 2005. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23: 1147-1157.
32. Wrzesinski, C., C. M. Paulos, L. Gattinoni, D. C. Palmer, A. Kaiser, Z. Yu, S. A. Rosenberg, and N. P. Restifo. 2007. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin. Invest. 117: 492-501. (Pubitemid 46203978)
33. Heemskerk, M. H., R. S. Hagedoorn, M. A. Van Der Hoorn, L. T. van der Veken, M. Hoogeboom, M. G. Kester, R. Willemze, and J. H. Falkenburg. 2007. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 109: 235-243.
34. Gattinoni, L., S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer, P. J. Spiess, L. N. Hwang, Z. Yu, C. Wrzesinski, D. M. Heimann, et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202: 907-912. (Pubitemid 41396891)
35. Klebanoff, C. A., H. T. Khong, P. A. Antony, D. C. Palmer, and N. P. Restifo. 2005. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26: 111-117.
36. + T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174: 2591-2601.
37. Turk, M. J., J. A. Guevara-Patino, G. A. Rizzuto, M. E. Engelhorn, S. Sakaguchi, and A. N. Houghton. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200: 771-782.
38. Cobbold, M., N. Khan, B. Pourgheysari, S. Tauro, D. McDonald, H. Osman, M. Assenmacher, L. Billingham, C. Steward, C. Crawley, et al. 2005. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202: 379-386. (Pubitemid 41126955)
39. Knabel, M., T. J. Franz, M. Schiemann, A. Wulf, B. Villmow, B. Schmidt, H. Bernhard, H. Wagner, and D. H. Busch. 2002. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat. Med. 8: 631-637. (Pubitemid 34633443)
40. Toebes, M., M. Coccoris, A. Bins, B. Rodenko, R. Gomez, N. J. Nieuwkoop, W. van de Kasteele, G. F. Rimmelzwaan, J. B. Haanen, H. Ovaa, and T. N. Schumacher. 2006. Design and use of conditional MHC class I ligands. Nat. Med. 12: 246-251. (Pubitemid 43214754)
41. + memory stem cells in graft-versus-host disease. Nat. Med. 11: 1299-1305.
42. A. U. van Lent, M. Nagasawa, M. M. van Loenen, R. Schotte, T. N. Schumacher, M. H. Heemskerk, H. Spits, and N. Legrand. 2007. Functional antigen-specific T cells produced in vitro using retroviral T cell receptor transfer into human hematopoietic progenitors. J. Immunol. 179: 4959-4968.
43. Zhao, Y., M. R. Parkhurst, Z. Zheng, C. J. Cohen, J. P. Riley, L. Gattinoni, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2007. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Res. 67: 2425-2429. (Pubitemid 46548926)